Global Scans · Psoriasis · Weekly Summary

• The psoriasis treatment is the last of three Bristol Myers drugs, each of which it forecasts will hit $4 billion in peak annual sales, due an approval decision in 2022. BioPharma Dive
• Denmark's Union Therapeutics A/S has begun a strategic collaboration with Innovent Biologics, Inc., over orismilast, a next-generation oral PDE4 inhibitor for inflammatory dermatology conditions that could compete directly with Amgen Inc.'s psoriasis blockbuster Otezla. Bioworld
• The autoimmune diseases segment is likely to register a fastest CAGR of 14.2% from 2026 to 2034 owing to the rising prevalence of conditions such as rheumatoid arthritis psoriasis and inflammatory bowel disease which require long term biological management. Market Data Forecast

Last updated: 03 August 2026